IC Directors' Meeting Highlights |
February 2, 2006
Discussion Items I. Biomarker Consortium Dr. Skirboll provided an overview of the soon to be implemented Biomarker Consortium. This is a public-private partnership whose membership includes the NIH, the FDA, industry, patient advocacy groups, and CMS. The FNIH will manage and coordinate this initiative. The purpose of this consortium is to promote the discovery, development, and qualification of biomarkers. The FNIH will manage and coordinate this consortium. The next steps for the Biomarkers Consortium are to: Assemble the Executive Committee and convene first meeting; finalize mission and vision — name the Consortium; develop the Consortium membership program; formalize business principles on IP and data access; develop communications plan; and identify and begin exemplary projects. Once in place, the Consortium will be publicly announced by all of the partners. Dr. Zerhouni thanked Dr. Skirboll for all of her work in getting this project off the ground. II. OPASI Presentations to IC Councils Dr. Kington informed the group that they have now chosen a search committee to start the process of selecting a Director for OPASI. He asked that all encourage potential candidates to apply for this position. Dr. Kington quickly reviewed a PowerPoint presentation that is being used to communicate an overview of the Office of Portfolio Analysis and Strategic Initiatives (OPASI) to groups such as FASEB and AAMC. He asks that an OPASI overview be presented to all the IC Advisory Councils during their next two rounds of meetings. Important points to make are:
The slides presented are a work in progress and Dr. Kington asked for any suggestions. Several suggestions were made. Talking points will also be made available. If anyone has comments or needs clarification, Dr. Kington asks that you contact him or Dr. Amy Bany. Dr. Zerhouni reminded all that OPASI was developed strategically to functionally integrate rather than consolidating ICs and that this decision was intellectually driven, not a structural change. III. Other Informational Items
Ann Brewer |
This page was last reviewed on September 21, 2006 . |
National Institutes of Health (NIH) |